Distinct receptor tyrosine kinase subsets mediate anti-HER2 drug resistance in breast cancer

Journal of Biological Chemistry

Volumn 292, Issue 2, 2017, Pages 748-759

  Alexander, Peter B ^a   Chen, Ru ^a   Gong, Chang ^b   Yuan, Lifeng ^a   Jasper, Jeff S ^a   Ding, Yi ^a   Markowitz, Geoffrey J ^a   Yang, Pengyuan ^a   Xu, Xin ^a   McDonnell, Donald P ^a   Song, Erwei ^b   Wang, Xiao Fan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; DIAGNOSIS; DISEASES; ENZYMES; MONOCLONAL ANTIBODIES; PATIENT TREATMENT; SIGNAL TRANSDUCTION; TUMORS;

CELLULAR SENESCENCE; CLINICAL PROGNOSIS; CRITICAL QUESTIONS; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2); RECEPTOR TYROSINE KINASE; SIGNALING PATHWAYS; TARGETED CANCER THERAPY; THERAPEUTIC STRATEGY;

DRUG THERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SENESCENCE; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRASTUZUMAB;

EID: 85009770686     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.754960     Document Type: Article

References (53)

1. Jemal, A., Center, M. M., DeSantis, C., and Ward, E. M. (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 19, 1893-1907
2. Citri, A., and Yarden, Y. (2006) EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7, 505-516
3. Moasser, M. M. (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469-6487
4. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182
5. Hynes, N. E., and Lane, H. A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354
6. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792
7. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684
8. Nahta, R., and Esteva, F. J. (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 8, 215
9. Vu, T., and Claret, F. X. (2012) Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62
10. Groenendijk, F. H., and Bernards, R. (2014) Drug resistance to targeted therapies: deja vu all over again. Mol. Oncol. 8, 1067-1083
11. Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D. P., Koeppen, H., et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509
12. Niederst, M. J., and Engelman, J. A. (2013) Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 6, re6
13. Alexander, P. B., and Wang, X. F. (2015) Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. Front. Med. 9, 134-138
14. Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B. A., Kamma, M., Friedman, P. N., Gelman, R., Iglehart, J. D., and Winer, E. P. (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13, 1198-1207
15. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93, 1852-1857
16. Lu, Y., Zi, X., and Pollak, M. (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334-341
17. Wang, Q., Quan, H., Zhao, J., Xie, C., Wang, L., and Lou, L. (2013) RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Lett. 340, 43-50
18. Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., Apicella, M., Migliardi, G., Galimi, F., Lauricella, C., Zanon, C., et al. (2013) Amplification of theMETreceptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673
19. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J. P., Tong, F., Speed, T., Spellman, P. T., DeVries, S., Lapuk, A., Wang, N. J., et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527
20. Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., Harris, J., and Spector, N. L. (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 103, 7795-7800
21. Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., and Rosen, N. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71
22. Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., and Arteaga, C. L. (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U.S.A. 109, 2718-2723
23. García-Echeverrá, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H. G., Cozens, R., Evans, D. B., Fabbro, D., Furet, P., Porta, D. G., Liebetanz, J., et al. (2004) In vivo antitumor activity of NVP-AEW541: a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5, 231-239
24. Roskoski, R., Jr. (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 356, 323-328
25. Yardley, D. A., Burris, H. A., 3rd, Markus, T., Spigel, D. R., Greco, F. A., Mainwaring, M., Waterhouse, D. M., Webb, C. D., and Hainsworth, J. D. (2009) Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin. Breast Cancer 9, 237-242
26. Modi, S., Seidman, A. D., Dickler, M., Moasser, M., D'Andrea, G., Moynahan, M. E., Menell, J., Panageas, K. S., Tan, L. K., Norton, L., and Hudis, C. A. (2005) A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res. Treat. 90, 157-163
27. Clemmons, D. R. (1997) Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 8, 45-62
28. Chang, Y. S., Wang, L., Liu, D., Mao, L., Hong, W. K., Khuri, F. R., and Lee, H. Y. (2002) Correlation between insulin-like growth factor-binding protein- 3 promoter methylation and prognosis of patients with stage I nonsmall cell lung cancer. Clin. Cancer Res. 8, 3669-3675
29. Wiley, A., Katsaros, D., Fracchioli, S., and Yu, H. (2006) Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16, 210-218
30. Kawasaki, T., Nosho, K., Ohnishi, M., Suemoto, Y., Kirkner, G. J., Fuchs, C. S., and Ogino, S. (2007) IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Neoplasia 9, 1091-1098
31. Rivenbark, A. G., Jones, W. D., Risher, J. D., and Coleman, W. B. (2006) DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells. Epigenetics 1, 32-44
32. Hudis, C. A. (2007) Trastuzumab: mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51
33. Spector, N. L., and Blackwell, K. L. (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27, 5838-5847
34. Kim, K. S., Kim, M. S., Seu, Y. B., Chung, H. Y., Kim, J. H., and Kim, J. R. (2007) Regulation of replicative senescence by insulin-like growth factorbinding protein 3 in human umbilical vein endothelial cells. Aging Cell 6, 535-545
35. Kim, K. S., Seu, Y. B., Baek, S. H., Kim, M. J., Kim, K. J., Kim, J. H., and Kim, J. R. (2007) Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol. Biol. Cell 18, 4543-4552
36. Elzi, D. J., Lai, Y., Song, M., Hakala, K., Weintraub, S. T., and Shiio, Y. (2012) Plasminogen activator inhibitor 1-insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc. Natl. Acad. Sci. U.S.A. 109, 12052-12057
37. Kojima, H., Kunimoto, H., Inoue, T., and Nakajima, K. (2012) The STAT3- IGFBP5 axis is critical for IL-6/gp130-induced premature senescence in human fibroblasts. Cell Cycle 11, 730-739
38. Kuilman, T., Michaloglou, C., Mooi, W. J., and Peeper, D. S. (2010) The essence of senescence. Genes Dev. 24, 2463-2479
39. Lowe, S. W., Cepero, E., and Evan, G. (2004) Intrinsic tumour suppression. Nature 432, 307-315
40. Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., Beach, D., and Serrano, M. (2005) Tumour biology: senescence in premalignant tumours. Nature 436, 642
41. Rodier, F., and Campisi, J. (2011) Four faces of cellular senescence. J. Cell Biol. 192, 547-556
42. Alexander, P. B., Yuan, L., Yang, P., Sun, T., Chen, R., Xiang, H., Chen, J., Wu, H., Radiloff, D. R., and Wang, X. F. (2015) EGF promotes mammalian cell growth by suppressing cellular senescence. Cell Res. 25, 135-138
43. Coppé, J. P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P. Y., and Campisi, J. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853-2868
44. Coppé, J. P., Desprez, P. Y., Krtolica, A., and Campisi, J. (2010) The senescence- associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118
45. Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., Nilsson, M. B., Gudikote, J., Tran, H., Cardnell, R. J., Bearss, D. J., et al. (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290
46. Zhou, J., Wang, J., Zeng, Y., Zhang, X., Hu, Q., Zheng, J., Chen, B., Xie, B., and Zhang, W. M. (2015) Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget 6, 44332-44345
47. Salt, M. B., Bandyopadhyay, S., and McCormick, F. (2014) Epithelial-tomesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 4, 186-199
48. Sharma, P., and Allison, J. P. (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205-214
49. Kastner, K., Margraf, J. T., Clark, T., and Streb, C. (2014) A molecular placeholder strategy to access a family of transition-metal-functionalized vanadium oxide clusters. Chemistry 20, 12269-12273
50. Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., Quackenbush, J. F., Stijleman, I. J., Palazzo, J., Marron, J. S., Nobel, A. B., et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167
51. Thompson, C. A. (2015) Biosimilar filgrastim approved, but with "placeholder" generic name. Am. J. Health Syst. Pharm. 72, 592-594
52. Schröder, M. S., Culhane, A. C., Quackenbush, J., and Haibe-Kains, B. (2011) survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 27, 3206-3208
53. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J., and Toussaint, O. (2009) Protocols to detect senescence-associated β-galactosidase (SA- βgal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798-1806